MedTrace Logo

Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy

NCT07358130 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 552

Last updated 2026-01-22

No results posted yet for this study

Summary

(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H. pylori infection, and (2) To investigate the influence of H. pylori antibiotic resistance, along with host CYP3A4, CYP2C19, and IL-1B -511 genotypes, on the eradication efficacy of H. pylori therapies.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

vonoprazan, tripotassium dicitrate bismuthate, amoxicilline

bismuth-amoxicillin-vonoprazan triple therapy

DRUG

rabeprazole, tripotassium dicitrate bismuthate, tetracycline, metronidazole

bismuth-based quadruple therapy

Sponsors & Collaborators

  • Kaohsiung Veterans General Hospital.

    collaborator OTHER

  • Kaohsiung Medical University

    lead OTHER

Principal Investigators

  • Deng-Chyang Wu, MD, PHD · Kaohsiung Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-21
Primary Completion
2027-11-15
Completion
2027-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07358130 on ClinicalTrials.gov